Featured Videos |view more
Although technically challenging, robotic abdominoperineal resection (APR) with robotic harvest of the rectus abdominus muscular flap can eliminate the need for a midline laparotomy, reduce wound infection rates and lead to faster recovery.
In this video, two MUSC Hollings Cancer Center neuro-oncologists, Scott M. Lindhorst, M.D., and David M. Cachia, M.D., discuss their experience with TTFields and the clinical trials they are leading in patients who have failed Avastin therapy.
Gerard A. Silvestri, M.D., a lung cancer pulmonologist at MUSC, led a study that shows that a new biomarker is 98 percent effective at distinguishing benign from malignant lung nodules.
Featured Articles and Documents |view more
To ensure its clinicians and researchers can help create new microbiome-based therapies, MUSC is ramping up its microbiome infrastructure, providing support in sequencing the microbiota and in analyzing the resulting datasets.
The Hollings Cancer Center at the Medical University of South Carolina is a National Cancer Institute-designated cancer center and the largest academic-based cancer research program in South Carolina. The cancer center comprises more than 120 faculty cancer scientists with an annual research funding portfolio of $44 million and a dedication to reducing the cancer burden in South Carolina. Hollings offers state-of-the-art diagnostic capabilities, therapies and surgical techniques within multidisciplinary clinics that include surgeons, medical oncologists, radiation therapists, radiologists, pathologists, psychologists and other specialists equipped for the full range of cancer care, including more than 200 clinical trials.